Physician profile
Ashley Shull Wilson
NPI 1407631435
$762.07
in general payments reported to CMS, 2019-2025
12 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $57.85 · 2024: $512 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $140.57 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.24 | 2024 | Caplyta |
| Abbvie INC. | $129.88 | 2024-2025 | |
| Boston Scientific Corporation | $83.30 | 2023-2025 | General - Pain Management |
| Novo Nordisk INC | $67.86 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $66.07 | 2023-2025 | |
| Amgen INC. | $30.45 | 2024-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $27.65 | 2024 | Rexulti |
| Alkermes, INC. | $27.56 | 2024 | Vivitrol |
| Exact Sciences Corporation | $20.78 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2024 | Farxiga |
| Organon LLC | $16.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.